View Post

Which Patients Should Get CDK4/6 Inhibitors?

In Clinical Trials by Barbara Jacoby

Some, however, are asking instead: who should not get them? By: Kristin Jenkins From: The approval of three cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors for the treatment of patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) advanced breast cancer has completely changed the way in which oncologists view and manage up to 75% of invasive breast …